ArticleMovement disorders clinical practice2020
A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy.
Article in Movement disorders clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dysphagia Prevalence in Progressive Supranuclear Palsy: A Systematic Review and Meta-Analysis.Dysphagia · 2024Pooled it
- Progressive Supranuclear Palsy-A Global Review.Movement disorders clinical practice · 2026Review
- Evaluating the Homogeneity of the PSP-RS Syndrome beyond Core Features.Movement disorders clinical practice · 2025Article
- A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.Nature communications · 2025Article
- Relationships between regional burden of tau pathology and age at death and disease duration in PSP.Parkinsonism & related disorders · 2024Article
- Clinical and neuroimaging characteristics of primary lateral sclerosis with overlapping features of progressive supranuclear palsy.European journal of neurology · 2024Article
- Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis.Clinical parkinsonism & related disorders · 2024Article
- Dysphagia in progressive supranuclear palsy: A scoping review.Clinical parkinsonism & related disorders · 2024Article
- Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials.Brain : a journal of neurology · 2023Article
- Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Protracted course progressive supranuclear palsy.European journal of neurology · 2022Article
- Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.BMJ neurology open · 2022Article
- Neuroprotection trial design in progressive supranuclear palsy: challenges and solutions.Alzheimer's & dementia (New York, N. Y.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundProgressive supranuclear palsy (PSP) causes major disability, shortens life, and as yet has no disease-modifying and little symptomatic treatment. A convenient prognostic tool is needed to assist patients, families, and clinicians in planning care.
objectivesWe calculated times to acquisition of certain disease milestones and death.
methodsWe followed a cohort of 417 patients with PSP-Richardson syndrome from 1995 to 2016, applying the Progressive Supranuclear Palsy Rating Scale (PSPRS) at each visit. We generated median times to acquisition of 13 milestones using the input variables of sex, onset age, rate of disease progression from motor symptom onset to initial visit, and PSPRS score at the baseline. Of the outcome milestones, 5 were stages of a new, provisional PSP staging system. The other 8 milestones comprised death and disabling levels of cognitive loss, gaze palsy, dysarthria, dysphagia, and gait/balance impairment.
resultsWe derived median times to milestones, with 25th and 75th percentiles and 95% confidence intervals of the median for baseline PSPRS scores from 25 to 65 (scale range, 0-100). Sex and initial progression velocity significantly influenced the death milestone, but not most of the others. Median time to death ranged from 4.8 years for a man with PSPRS score of 25 and a slow progression velocity from onset to initial visit of 0.51 PSPRS points/month to 1.8 years for a woman with PSPRS 65 and rapid initial velocity of 2.25 points/month.
conclusionsWe have created a convenient, inexpensive, noninvasive reference for counseling patients with PSP-Richardson syndrome on approximate time to encountering 13 life-altering disease milestones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.